Advanced Bifurcation Systems Inc. Acquires Svelte Medical Systems, Inc.
The acquired portfolio includes Svelte's drug-eluting coronary stents, all intellectual property, and the related comprehensive set of US and international regulatory approvals and filings: U.S. Food and Drug Administration ("FDA") Premarket Approval ("PMA");
This acquisition places ABS in a small group of select global companies possessing an FDA-approved drug eluting coronary stent. Combined with ABS's innovative platform (for which ABS was awarded FDA's Breakthrough Device Designation), the acquisition will accelerate ABS's development pathway for its bifurcation-focused technology platform and materially strengthen ABS's presence in the global interventional cardiology market.
"As we advance our mission to transform the treatment of coronary bifurcation lesions, this acquisition will expand our commercial portfolio and represents a pivotal strategic milestone," said
For more information about Advanced Bifurcation Systems and its revolutionary approach to coronary artery bifurcation stenting, visit www.advancedbifurcation.com.
Contacts:
Advanced Bifurcation Systems, Inc.
Chairman & CEO
[email protected]
President & COO
[email protected]
CAO/CFO
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/advanced-bifurcation-systems-inc-acquires-svelte-medical-systems-inc-302753614.html
SOURCE Advanced Bifurcation Systems
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xinhua Silk Road: Sub-venue of 16th China-Russia culture fair opens in Jiamusi, NE China's Heilongjiang Province
- IntelexVision Rebrands to Eluviant and Unveils Its Aurora Flow AI Model That Understands Motion in Surveillance
- Website Expands Educational Resources for Activ Gift Card Users
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share